All In Biotech

NDA 214408 · Accord Hlthcare

Pemetrexed Disodium

Pemetrexed Disodium · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jul 19, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,475

329 Phase 3, 251 recruiting

FAERS reports

3,897

3,831 serious, 686 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 850MG BASE/34ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 100MG BASE/4ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 1GM BASE/40ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 500MG BASE/20ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Pemetrexed Disodium" as an intervention, any sponsor and status, largest first.

All 1,475 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myelosuppression454
  • malignant neoplasm progression383
  • anaemia196
  • diarrhoea182
  • nausea179
  • platelet count decreased150
  • death147
  • rash144
  • neutropenia139
  • white blood cell count decreased139
  • pyrexia137
  • neutrophil count decreased135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200425
20058
200611
200716
200813
200910
201050
201180
2012115
201333
201427
201522
201641
201783
2018212
2019558
2020484
2021472
2022301
2023248
2024364
2025399
2026325

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pemetrexed Disodium (Pemetrexed Disodium)

2024 spending

$2.4M

Beneficiaries

411

1,858 claims

Per beneficiary

$5,750

$413.77 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,633,240
2023$2,502,312
2024$2,363,306

Part B: Pemetrexed Disodium (Pemetrexed Disodium) · HCPCS J9297

2024 spending

$57K

Beneficiaries

206

574 claims

Per beneficiary

$275

2024 ASP limit $1.28 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$81,682
2024$56,717

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Accord Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.